Pulmatrix, a Lexington, Mass.-based clinical stage biotechnology company, has promoted Robert Clarke, Ph.D., to the position of CEO and to the board of directors.

Previously, Clarke served as Pulmatrix’s chief scientific officer and vice president of R&D. Joining Pulmatrix in 2004, he has helped develop Pulmatrix technologies, iCALM and iSPERSE, for treatment of respiratory disease. Previous to Pulmatrix, Clarke was an associate director of life sciences at Alkermes, focused mainly on developing inhaled therapeutic products with the AIR technology platform.

Clarke has over 12 years of industry experience and over 20 years total experience focused on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine, leading to co-authorship of over 80 chapters, papers and abstracts.